Sawai Group Holdings will implement a company split effective September 1, 2026, to transfer the non-alcoholic fatty liver disease treatment app business to a wholly owned subsidiary, Sawai Pharmaceutical Co., Ltd., aiming to improve business efficiency and corporate value.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4887","jir_company_name":"Sawai Group Holdings Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-06-25","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/06\/4887-20260625-02.pdf","jir_short_summary":"Sawai Group Holdings will implement a company split effective September 1, 2026, to transfer the non-alcoholic fatty liver disease treatment app business to a wholly owned subsidiary, Sawai Pharmaceutical Co., Ltd., aiming to improve business efficiency and corporate value.","jir_summary":"### Overview of Business Reorganization and Company Split\nSawai Group Holdings will implement a company split effective September 1, 2026, to transfer the NASH app business to its wholly owned subsidiary Sawai Pharmaceutical Co., Ltd. This split is a simplified absorption-type split based on Article 784, Paragraph 2 of the Companies Act, with no allotment of shares or providing consideration. Details of assets and liabilities will be announced once finalized, with the aim of streamlining operations and enhancing sustainable corporate value. There will be no change in the company's capital stock, basic management structure, location, or representative as a result of the split.\n\n### Future Outlook and Impact\nThis company split is a business reorganization between the company and its wholly owned subsidiary, and its impact on consolidated performance is expected to be minimal. By promoting the NASH app business and accelerating commercialization, the company aims to enhance its value as a comprehensive healthcare company. Details regarding finalized assets, liabilities, and schedule will be disclosed as they become available.","jir_financial_highlights":"Total Assets: Unknown (Unknown)\nTotal Liabilities: 100 million yen (Unknown)\nNet Income attributable to owners of parent: 10,438 million yen (YoY unknown)","jir_category":"","jir_hashtags":"#SawaiGroupHoldings, #OrganizationalRestructuring, #JapanStocks","jir_key_figures":"Total Assets: Unknown\nTotal Liabilities: 100 million yen\nNet Income attributable to owners of parent: 10,438 million yen","jir_meta_title":"\u3010Sawai Group Holdings\u3011Notice of Business Reorganization and Stock Split\uff5cJune 2026","jir_meta_description":"Sawai Group Holdings plans to carry out a company split in September 2026 to streamline healthcare operations and enhance corporate value. Details can be found in the IR materials.","jir_og_title":"\u3010Sawai Group\u3011Notice of Business Reorganization and Stock Split\uff5cJune 2026","jir_og_description":"Sawai Group will implement a company split in September 2026 to accelerate healthcare business development. Please see the IR materials for details.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":8760,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"corporate_restructuring","footnotes":""},"sector":[],"importance":[],"class_list":["post-69909","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n